Exact Sciences Corporation

All live lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star one on your telephone keypad. We do ask that you limit yourself to one question today. I would now like to turn the conference over to Derek Lecko, Vice President, Investor Relations. Please go ahead, sir.

Thanks, operator. Thank you for joining us for Exact Sciences' fourth quarter 2024 conference call. On the call today are Kevin Conroy, the company's chairman and CEO, and Aaron Bloomer, our chief financial officer. Brian Baranek, our general manager of precision oncology, will also be available for questions. Exact Sciences issued a news release earlier this afternoon detailing our fourth quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release, and descriptions of the risks and uncertainties associated with exact sciences are included in our SEC filings. Both can be accessed through our website. I'll now turn the call over to Kevin.

Thanks, Derek. Good afternoon, everyone. Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. We are making this a reality by extending and leveraging our platform. Highlights in 2024 include delivering more than 4.6 million results to patients with our portfolio of cancer tests, growing core revenue 11%, while non-GAAP operating expenses grew just 2%. Increasing EBITDA by 48% and more than doubling free cash flow. Securing FDA approval and Medicare pricing for Cologuard Plus, our next-generation colon cancer screening test. Completing two studies for OncoDetect, our molecular residual disease test. generating evidence for our liquid biopsy colon cancer screening test, as well as our multi-cancer screening test, CancerGuard, and being recognized as a great place to work for the sixth consecutive year. This year, we'll increase adoption of our current tests and launch three new tests. ExactScience's scale and reach with the large commercial engine and tens of millions of additional touch points with patients and healthcare providers will power continued leadership across the largest impact opportunities in cancer diagnostics. We'll also create an even better customer experience with our secure ExactNexus technology platform. Aaron will now discuss our fourth quarter financial results and outlook for 2025.